American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) Registry
NCT ID: NCT02674100
Last Updated: 2025-02-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
500 participants
OBSERVATIONAL
2016-01-31
2030-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators seek a better understanding of the uses of ablation in the treatment of unresectable soft tissue pancreatic tumors and the limitations, concerns and complications that earlier users have.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
International Study on Treatment of Patients With Metastatic Colorectal Liver Lesions Patients With IRE
NCT07191548
Irreversible Electroporation for Inoperable Hepatic and Pancreatic Malignancy
NCT02822716
Hepatic Resection for Metastatic Pancreatic Cancer
NCT02892305
Endoscopic Radiofrequency Ablation of Celiac Ganglion for Pain Management and Improvement of Quality of Life in Patients With Unresectable Pancreatic Cancer
NCT05535894
Safety Study of Radiofrequency Ablation of Locally Advanced Pancreatic Cancer
NCT01628458
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The rationale for creating this multi-center clinical database is to optimally collect clinical and pathological data on patients with neoplasms in order to facilitate future clinical observational and outcomes-based research.
Inclusion Criteria
Patients will be considered eligible for inclusion into the database if they meet the following eligibility criteria:
Evidence/suspicion of Pancreatic neoplasm ≥ 18 years of age
Exclusion Criteria Patients will be considered ineligible for inclusion into the database if they are not able to give consent.
Inclusion of Women, Minorities and Vulnerable Subjects This protocol will include women and minority populations. Vulnerable subjects (prisoners, children, mentally disabled persons) will not be included in the study population.
Primary Study Objective(s):
To provide insight in treatment selection and treatment outcome of Pancreatic IRE in order to develop an evidence base such that physicians can provide the best possible care to patients with Pancreatic cancer requiring surgical intervention.
Secondary Study Objective(s):
To provide data on adverse events and complications related to IRE treatment.
The AHPBA will be responsible for data collection and will periodically audit the data for quality assurance purposes. The AHPBA will review outcomes reported by each participating Research Institution and if outcomes are in the lower percentile, the investigators will be offered support to analyze the reasons for the suboptimal outcomes and may seek support to improve outcomes. The participating Research Institutions will receive a certificate annually that acknowledges their participation in the Research Project.
Goal and Aims of Registry?
The Specific Aims are:
* Gain a better understanding of the uses of ablation in the treatment of unresectable soft tissue pancreatic tumors
* Understand the limitations, concerns, and complications that earlier users of ablation in the treatment of unresectable soft tissue pancreatic tumors have
Create a multi-institutional group that will both enroll in this registry study, but more importantly enroll in future, prospective ablation in the treatments of unresectable soft tissue pancreatic tumors studies. Any patient undergoing a soft tissue ablation may be included in this study. To confirm, you will always own your data and the registry will be used as data storage until you release your data for evaluation on a project-by-project basis.
What Patients are Eligible?
• Any patient to which the treating physician believes that ablation of their soft tissue would be feasible in the care of their disease.
Patients who can be followed and can provide outcome data to achieve the Goals and Aims of the Registry.
To participate, the only thing we need to obtain from your site is a regulatory approval letter stating that it is acceptable to collaborate with your patients de-identified data (sample data collection protocol is attached) and that you will be consenting your patients to this data collaboration (The Registry).
Case report forms/ data collection sheets are attached The data entry will be web based. All treatments must be entered-not just the first treatment. All follow up-up to 2 years or until death of patient-must be entered. Common follow up is every 3-4 months for first year and every 6 months for second year. In order to ensure data accuracy we require that, for the first 5 patients entered, the data sheets and their supporting documentation (de-identified labs, treatment dictation, etc.) be sent to us so we can make sure the data entry is correct and complete (e.g., lesion dimensions, measures of response or progression, etc.).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Registry
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Non-removable implants with metal parts near target lesion
* Myocardial infarction within 3 months prior to enrollment
* Not suitable for general endotracheal anesthesia
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Americas Hepato-Pancreato-Biliary Association
UNKNOWN
University of Louisville
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Robert C. Martin
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert Martin, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Louisville
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama Birmingham
Birmingham, Alabama, United States
University of California San Diego
San Diego, California, United States
University of Colorado
Denver, Colorado, United States
University of South Florida
Tampa, Florida, United States
Augusta University
Augusta, Georgia, United States
University of Louisville
Louisville, Kentucky, United States
Johns Hopkins Hospital
Baltimore, Maryland, United States
Atlantic Health
Millburn, New Jersey, United States
Northwell Health Cancer Institute
Lake Success, New York, United States
Gibbs Cancer Research, Spartanburg Regional Healthcare System
Spartanburg, South Carolina, United States
Methodist Digestive Institute
Dallas, Texas, United States
McGill University
Montreal, Quebec, Canada
Sanno Hospital
Tokyo, Japan, Japan
Centro Medico
Mexico City, , Mexico
National Taiwan University
Taipei, , Taiwan
Freeman Hospital
High Heaton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
06-326
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.